RemeGen (9995) Stock Overview
A biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
9995 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
RemeGen Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$79.70 |
| 52 Week High | HK$126.60 |
| 52 Week Low | HK$53.90 |
| Beta | 0.43 |
| 1 Month Change | -3.57% |
| 3 Month Change | -16.81% |
| 1 Year Change | 46.37% |
| 3 Year Change | 133.38% |
| 5 Year Change | -31.94% |
| Change since IPO | 14.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9995 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 19.4% | -4.2% | -4.7% |
| 1Y | 46.4% | -10.7% | -4.2% |
Return vs Industry: 9995 exceeded the Hong Kong Biotechs industry which returned -10.7% over the past year.
Return vs Market: 9995 exceeded the Hong Kong Market which returned -4.2% over the past year.
Price Volatility
| 9995 volatility | |
|---|---|
| 9995 Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 16.3% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 9995 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9995's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 3,048 | Jianmin Fang | www.remegen.com |
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors.
RemeGen Co., Ltd. Fundamentals Summary
| 9995 fundamental statistics | |
|---|---|
| Market cap | HK$60.56b |
| Earnings (TTM) | HK$1.49b |
| Revenue (TTM) | HK$3.90b |
Is 9995 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9995 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.38b |
| Cost of Revenue | CN¥444.42m |
| Gross Profit | CN¥2.94b |
| Other Expenses | CN¥1.65b |
| Earnings | CN¥1.29b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.31 |
| Gross Margin | 86.86% |
| Net Profit Margin | 38.20% |
| Debt/Equity Ratio | 50.9% |
How did 9995 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/29 12:52 |
| End of Day Share Price | 2026/06/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RemeGen Co., Ltd. is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhishun Siu | CCB International Securities Limited |
| Shun Kei Law | CCB International Securities Limited |
| Jin Zhang | China International Capital Corporation Limited |